These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39269987)

  • 1. Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease.
    Alessio GD; Silvestrini CMA; Elói-Santos SM; Gontijo ED; Sales Júnior PA; Vitelli-Avelar DM; Sathler-Avelar R; Wendling APB; Teixeira-Carvalho A; de Lana M; Martins-Filho OA
    PLoS Negl Trop Dis; 2024 Sep; 18(9):e0012487. PubMed ID: 39269987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accomplishing the genotype-specific serodiagnosis of single and dual Trypanosoma cruzi infections by flow cytometry Chagas-Flow ATE-IgG2a.
    Alessio GD; de Araújo FF; Sales Júnior PA; Gomes MS; Amaral LRD; Pascoal Xavier MA; Teixeira-Carvalho A; de Lana M; Martins-Filho OA
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006140. PubMed ID: 29462135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of TcI/TcVI/TcII Chagas-Flow ATE-IgG2a for universal and genotype-specific serodiagnosis of Trypanosoma cruzi infection.
    Alessio GD; de Araújo FF; Côrtes DF; Sales Júnior PA; Lima DC; Gomes MS; do Amaral LR; Xavier MA; Teixeira-Carvalho A; Martins-Filho OA; de Lana M
    PLoS Negl Trop Dis; 2017 Mar; 11(3):e0005444. PubMed ID: 28333926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Chagas-Flow ATE-IgG1 for advanced universal and Trypanosoma cruzi Discrete Typing Units-specific serodiagnosis of Chagas disease.
    Alessio GD; de Araújo FF; Silva JS; Júnior PAS; de Souza Gomes M; do Amaral LR; Ramírez JD; Flórez C; Teixeira-Carvalho A; de Barros Pinheiro M; de Lana M; Martins-Filho OA
    Sci Rep; 2020 Aug; 10(1):13296. PubMed ID: 32764546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovations in diagnosis and post-therapeutic monitoring of Chagas disease: Simultaneous flow cytometric detection of IgG1 antibodies anti-live amastigote, anti-live trypomastigote, and anti-fixed epimastigote forms of Trypanosoma cruzi.
    Alessio GD; Côrtes DF; Machado de Assis GF; Júnior PA; Ferro EA; Antonelli LR; Teixeira-Carvalho A; Martins-Filho OA; de Lana M
    J Immunol Methods; 2014 Nov; 413():32-44. PubMed ID: 25064148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lineage-specific rapid diagnostic tests can resolve Trypanosoma cruzi TcII/V/VI ecological and epidemiological associations in the Argentine Chaco.
    Murphy N; Macchiaverna NP; Victoria Cardinal M; Bhattacharyya T; Mertens P; Zeippen N; Gustin Y; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2019 Sep; 12(1):424. PubMed ID: 31522683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity.
    Zingales B
    Acta Trop; 2018 Aug; 184():38-52. PubMed ID: 28941731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.
    Rumi MM; Pérez Brandán C; Gil JF; D'Amato AM; Ragone PG; Lauthier JJ; Tomasini N; Cimino RO; Orellana V; Lacunza CD; Nasser JR; Basombrío MA; Diosque P
    Acta Trop; 2013 Oct; 128(1):130-6. PubMed ID: 23880286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trypanosoma cruzi: Genetic diversity influences the profile of immunoglobulins during experimental infection.
    dos Santos DM; Talvani A; Guedes PM; Machado-Coelho GL; de Lana M; Bahia MT
    Exp Parasitol; 2009 Jan; 121(1):8-14. PubMed ID: 18848935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection.
    Fernández MC; González Cappa SM; Solana ME
    Exp Parasitol; 2010 Feb; 124(2):172-80. PubMed ID: 19747482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TcI, TcII and TcVI Trypanosoma cruzi samples from Chagas disease patients with distinct clinical forms and critical analysis of in vitro and in vivo behavior, response to treatment and infection evolution in murine model.
    Oliveira MT; Branquinho RT; Alessio GD; Mello CGC; Nogueira-de-Paiva NC; Carneiro CM; Toledo MJO; Reis AB; Martins-Filho OAM; Lana M
    Acta Trop; 2017 Mar; 167():108-120. PubMed ID: 27908747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease.
    Moreno M; D'ávila DA; Silva MN; Galvão LM; Macedo AM; Chiari E; Gontijo ED; Zingales B
    Mem Inst Oswaldo Cruz; 2010 Nov; 105(7):918-24. PubMed ID: 21120364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lineage-specific rapid diagnostic test (Chagas Sero K-SeT) identifies Brazilian Trypanosoma cruzi II/V/VI reservoir hosts among diverse mammalian orders.
    McClean MCW; Bhattacharyya T; Mertens P; Murphy N; Gilleman Q; Gustin Y; Zeippen N; Xavier SCC; Jansen AM; Miles MA
    PLoS One; 2020; 15(1):e0227828. PubMed ID: 31951634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
    Martins HR; Silva RM; Valadares HM; Toledo MJ; Veloso VM; Vitelli-Avelar DM; Carneiro CM; Machado-Coelho GL; Bahia MT; Martins-Filho OA; Macedo AM; Lana M
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3282-9. PubMed ID: 17638698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic, functional and serological aspects of genotypic-specific immune response of experimental T. cruzi infection.
    da Silveira-Lemos D; Alessio GD; Batista MA; de Azevedo PO; Reis-Cunha JL; Mendes TAO; Lourdes RA; de Lana M; Fujiwara RT; Filho OAM; Bartholomeu DC
    Acta Trop; 2021 Oct; 222():106021. PubMed ID: 34161815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
    de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
    Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study.
    Andrade MC; Oliveira Mde F; Nagao-Dias AT; Coêlho IC; Cândido Dda S; Freitas EC; Coelho HL; Bezerra FS
    Rev Soc Bras Med Trop; 2013; 46(6):776-8. PubMed ID: 24474023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.
    Balouz V; Melli LJ; Volcovich R; Moscatelli G; Moroni S; González N; Ballering G; Bisio M; Ciocchini AE; Buscaglia CA; Altcheh J
    J Clin Microbiol; 2017 Dec; 55(12):3444-3453. PubMed ID: 28978686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.